Rakovina Therapeutics Adds Yale Brain Tumor Center Director to Scientific Advisory Board
Event summary
- Rakovina Therapeutics appointed Dr. Ranjit Bindra, MD, PhD, Scientific Director of the Yale Brain Tumor Center, to its Scientific Advisory Board on September 17, 2026.
- Dr. Bindra's research focuses on DNA repair vulnerabilities in cancer, particularly in IDH1/2-mutant tumors, and he has led clinical trials evaluating PARP inhibitors.
- The company received a $920,846.10 SR&ED tax refund, including interest, to support its pipeline advancements.
- Rakovina granted 2,910,500 stock options to consultants, employees, officers, and directors at an exercise price of $0.20 per share.
The big picture
Rakovina Therapeutics is strengthening its scientific advisory board with a clinician-scientist who has successfully translated DNA repair biology into clinical trials. This move aligns with the broader industry trend of leveraging AI-powered drug discovery to develop targeted cancer therapies, particularly for challenging indications like brain tumors. The company's recent tax refund and stock option grants also reflect its commitment to advancing its pipeline and attracting talent.
What we're watching
- Clinical Translation
- How Dr. Bindra's expertise will accelerate Rakovina's programs toward IND-enabling studies and clinical trials.
- Pipeline Advancement
- The pace at which the SR&ED tax refund will support in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program.
- Strategic Partnerships
- Whether Rakovina can leverage Dr. Bindra's network to form new collaborations or attract pharmaceutical partners.